PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsIrritable bowel syndrome
MeSH D043183 - irritable bowel syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D003109:Functional colonic diseases
25 Companies
2 Drugs
$
Success rate
D043183: 
Irritable bowel syndrome
46 Companies
11 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Salix PharmaceuticalsRifaximin Xifaxan 2024-06-19 2004-05-25   
TevaLubiprostone Lubiprostone  2022-01-18   
MylanLinaclotide Linaclotide  2021-02-09   
AbbVieLinaclotide Constella  2012-11-26   
Linaclotide Linzess 2024-01-28 2012-08-30 $1,004 M Q4/23-Q3/24 
Eluxadoline Viberzi 2025-03-14 2015-05-27   
AllerganEluxadoline Truberzi  2016-09-19   
Aurobindo PharmaLinaclotide Linaclotide  2023-02-07   
Dr Reddys LaboratoriesLubiprostone Lubiprostone  2022-02-08   
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
65%
13/20
Phase 2
51%
23/45
Phase 3
64%
27/42
Approved: 13Overall Success rate: 21%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
GSK
Ademetionine,
Pexacerfont,
Corticorelin,
EMICERFONT,
SOLABEGRON,
TALNETANT,
VERUCERFONT,
Gsk3352589
AbbVie
Linaclotide,
Eluxadoline,
Ademetionine
Allergan
Eluxadoline,
REZATOMIDINE,
Evidence
Dr Reddys Laboratories
Lubiprostone
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use